微血管性与血管痉挛性心绞痛患者的系统性微血管功能障碍
研究纳入81例受试者(59例微血管性心绞痛、11例血管痉挛性心绞痛、11例对照),基于侵入性冠状动脉功能检测分组,并行臀肌活检离体阻力动脉肌图检测。结果显示微血管性心绞痛和血管痉挛性心绞痛患者均存在外周阻力动脉内皮依赖性舒张受损及收缩反应增强,提示系统性微血管异常。
要点
- 微血管性心绞痛患者外周阻力动脉对乙酰胆碱的最大舒张反应降低,内皮依赖性舒张受损。
- 微血管性心绞痛和血管痉挛性心绞痛患者对内皮素-1及血栓素激动剂的收缩反应均增强。
- 阻力动脉对内皮素-1的收缩敏感性约为血栓素激动剂U46619的50倍。
核心结论
- 微血管性心绞痛和血管痉挛性心绞痛患者普遍存在系统性微血管异常,表现为内皮功能障碍和收缩反应增强,机制可能涉及内皮素-1。
研究设计与样本
- 前瞻性研究纳入81例受试者(62岁,69%女性,59例微血管性心绞痛、11例血管痉挛性心绞痛、11例对照),基于侵入性冠状动脉功能检测(乙酰胆碱和腺苷)分组,行臀肌皮下脂肪活检获取阻力动脉进行肌图检测。
主要发现
- 微血管性心绞痛患者对乙酰胆碱的最大舒张反应低于对照(中位数77.6% vs. 98.7%,差值95%CI 2.3-38%,P=0.0047)。
- 微血管性心绞痛患者对内皮素-1的最大收缩反应高于对照(中位数121% vs. 100%,中位数差值95%CI 4.7-45%,P=0.015)。
- 微血管性心绞痛患者对U46619的收缩反应高于对照(143% vs. 109%,差值95%CI 13-57%,P=0.003)。
- 血管痉挛性心绞痛患者对乙酰胆碱最大舒张反应降低(中位数79.0% vs. 98.7%,P=0.03),对内皮素-1收缩反应增强(中位数125% vs. 100%,P=0.02)。
- 各组阻力动脉对内皮素-1的收缩敏感性约为U46619的50倍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Coronary microvascular dysfunction and/or vasospasm are potential causes of ischaemia in patients with no obstructive coronary artery disease (INOCA). We tested the hypothesis that these patients also have functional abnormalities in peripheral small arteries. METHODS AND RESULTS: Patients were prospectively enrolled and categorised as having microvascular angina (MVA), vasospastic angina (VSA) or normal control based on invasive coronary artery function tests incorporating probes of endothelial and endothelial-independent function (acetylcholine and adenosine). Gluteal biopsies of subcutaneous fat were performed in 81 subjects (62 years, 69% female, 59 MVA, 11 VSA, and 11 controls). Resistance arteries were dissected enabling study using wire myography. Maximum relaxation to ACh (endothelial function) was reduced in MVA vs. controls [median 77.6 vs. 98.7%; 95% confidence interval (CI) of difference 2.3-38%; P = 0.0047]. Endothelium-independent relaxation [sodium nitroprusside (SNP)] was similar between all groups. The maximum contractile response to endothelin-1 (ET-1) was greater in MVA (median 121%) vs. controls (100%; 95% CI of median difference 4.7-45%, P = 0.015). Response to the thromboxane agonist, U46619, was also greater in MVA (143%) vs. controls (109%; 95% CI of difference 13-57%, P = 0.003). Patients with VSA had similar abnormal patterns of peripheral vascular reactivity including reduced maximum relaxation to ACh (median 79.0% vs. 98.7%; P = 0.03) and increased response to constrictor agonists including ET-1 (median 125% vs. 100%; P = 0.02). In all groups, resistance arteries were ≈50-fold more sensitive to the constrictor effects of ET-1 compared with U46619. CONCLUSIONS: Systemic microvascular abnormalities are common in patients with MVA and VSA. These mechanisms may involve ET-1 and were characterized by endothelial dysfunction and enhanced vasoconstriction. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov registration is NCT03193294.
引用
- Ford TJ, Rocchiccioli P, Good R, et al. Systemic microvascular dysfunction in microvascular and vasospastic angina. Eur Heart J. 2018. PMID: 30165438. doi:10.1093/eurheartj/ehy529
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。